reumacillin 150 mg kapseli
schering oy - d-penicillaminum - kapseli - 150 mg - penisillamiini
penicillamin 125 mg tabletti, kalvopäällysteinen
eli lilly finland oy ab - penicillaminum - tabletti, kalvopäällysteinen - 125 mg - penisillamiini
penicillamin 250 mg tabletti, kalvopäällysteinen
eli lilly finland oy ab - penicillaminum - tabletti, kalvopäällysteinen - 250 mg - penisillamiini
metalcaptase 150 mg enterotabletti
abbott gmbh & co. kg - d-penicillaminum - enterotabletti - 150 mg - penisillamiini
sutent
pfizer limited - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib accord
accord healthcare s.l.u. - sunitinibi - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiset aineet - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
bavencio
merck europe b.v. - avelumab - neuroendokriiniset kasvaimet - muut antineoplastiset aineet, monoklonaaliset vasta-aineet - bavencio on merkitty monoterapiana aikuispotilailla, joilla on metastaattinen merkel-solukarsinooma (mcc). bavencio yhdessä axitinib on tarkoitettu käytettäväksi ensilinjan hoitoon aikuispotilaille, joilla on pitkälle edennyttä munuaissyöpää (rcc). bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc) who are progression-free following platinum‑based chemotherapy.
sunitinib ratiopharm 12.5 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 12.5 mg - sunitinibi
sunitinib ratiopharm 25 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 25 mg - sunitinibi
sunitinib ratiopharm 37.5 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 37.5 mg - sunitinibi